Live Analyst Rating Changes 1526 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/Douglas Miehm
RBC
Douglas Miehm
RBC Capital
Wall Street Analyst
★★★☆☆
#1677
on 13Foresight · ranked by our own returns
38%
Success Rate
-8.7%
Average Return
3 of 8 calls profitable · -12.0% vs benchmark
📈 Across the calls we could measure, roughly 38% of Douglas Miehm's ratings turned a profit when each position was held for 1 year — averaging -8.7% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

44 Buy 25 Hold 0 Sell
Douglas's Stock Coverage 17 ratings · 2026-06-21
Company Date Position Consensus ⓘ Price Target ⓘ 1-Yr Return
TSE:DHT.UN
DRI Healthcare
 May 15, 2026 BUY Strong Buy
+10.3% avg upside
6 analysts
$21.00
16.91% Upside
 ·
TSE:WELL
WELL Health Technologies Corp
 May 10, 2026 BUY Strong Buy
+61.9% avg upside
9 analysts
$7.00
67.97% Upside
 ·
TSE:DR
Medical Facilities
 May 10, 2026 HOLD Buy
-3.2% avg upside
2 analysts
$19.00
6.66% Upside
 ·
TSE:GUD
Knight Therapeutics
 May 08, 2026 BUY Strong Buy
-10.7% avg upside
7 analysts
$9.50
2.41% Upside
 ·
AUPH
Aurinia Pharmaceuticals
 May 08, 2026 HOLD Strong Buy
-7.2% avg upside
12 analysts
$15.00
8.87% Downside
 +8.1%
LGND
Ligand Pharma
 May 07, 2026 BUY Strong Buy
-20.8% avg upside
15 analysts
$262.00
4.67% Downside
 +25.1%
MNKD
MannKind
 May 07, 2026 HOLD Buy
+78.6% avg upside
22 analysts
$4.75
20.54% Upside
 -6.8%
TSE:BHC
Bausch Health Companies
 Apr 30, 2026 HOLD Buy
+809.1% avg upside
29 analysts
$12.75
94.07% Upside
 ·
PCRX
Pacira Pharmaceuticals
 Apr 30, 2026 HOLD Buy
+74.3% avg upside
21 analysts
$24.00
7.44% Upside
 -11.2%
BLCO
Bausch + Lomb Corporation
 Apr 30, 2026 BUY Buy
+30.8% avg upside
19 analysts
$21.00
41.32% Upside
 -4.5%
VHI
Valhi
 Mar 19, 2026 BUY Sell
+67.0% avg upside
3 analysts
$7.77
42.51% Downside
 +7.7%
ONCY
Oncolytics Biotech
 Nov 19, 2025 BUY Strong Buy
+652.6% avg upside
12 analysts
$3.50
264.58% Upside
 -18.2%
TLRY
Tilray
 Oct 08, 2021 HOLD Hold
+88.2% avg upside
23 analysts
$19.00
301.66% Upside
 -69.8%
FR:ABVX
Abivax SA
 Jun 23, 2021 BUY Strong Buy
-63.5% avg upside
3 analysts
$22.00
74.11% Downside
 ·
ACHV
Achieve Life Sciences
 Aug 04, 2016 HOLD Strong Buy
+211.2% avg upside
12 analysts
$1.00
79.33% Downside
 ·
IMRSQ
IMRIS
 Nov 06, 2013 HOLD Strong Buy
+3452280.9% avg upside
3 analysts
$2.30
2737995.14% Upside
 ·
TSE:CSCI
COSCIENS Biopharma
 Feb 05, 2009 BUY Strong Buy
+472.1% avg upside
8 analysts
 — ·
🔒 12 more ratings — with price targets, crowd consensus and our measured returns.
Sign in free to unlock See Pro plans
Free account unlocks every analyst's full coverage table.
Douglas Miehm — Frequently Asked Questions
How accurate are Douglas Miehm's stock ratings?
Based on the calls 13Foresight could measure, about 38% of Douglas's ratings were profitable over a one-year hold, with an average return of -8.7% per rating, or -12.0% versus the S&P 500. We score every analyst the same way, from historical prices.
How is Douglas ranked on 13Foresight?
Douglas Miehm is currently ranked #1677 with a 3-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does Douglas cover?
Douglas most recently has ratings on TSE:DHT.UN, TSE:WELL, TSE:DR, TSE:GUD, AUPH, LGND, MNKD, TSE:BHC, PCRX, BLCO, VHI, ONCY and 5 more. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.